Banking
Jim Cramer: Merck is a buy after the drugmaker’s post-earnings dip — here’s why
[ad_1] Jim Cramer’s daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio. Merck : The drugmaker reported a…
[ad_1] Jim Cramer’s daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio. Merck : The drugmaker reported a…
[ad_1] Check out the companies making headlines in midday trading. EchoStar — EchoStar announced a corporate reorganization one week after closing its merger with…